orthopedic repair, enabling physicians to treat conditions that directly impact patients' lives. The company’s lead candidate, OsteoAdapt SP™, is an investigational biologic being evaluated in a Phase I/II clinical trial for patients with degenerative disc disease, a condition characterized by the deterioration of spinal joints that results in pain and dysfunction, and combines Theradaptive's next-generation engineered protein AMP2™, a modified, adhesive variant of the powerful bone-forming growth factor bone morphogenetic protein-2 (BMP-2), with a synthetic bone graft.